Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Phase contrast magnetic resonance imaging

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    109 result(s) found for: Phase contrast magnetic resonance imaging. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2021-003825-31 Sponsor Protocol Number: GDX-44-015 Start Date*: 2022-02-28
    Sponsor Name:Guerbet
    Full Title: Gadopiclenol Pharmacokinetics, Safety and Efficacy in Pediatric Patients < 2 Years of Age Undergoing Contrast-enhanced MRI P/0145/2019
    Medical condition: Known or highly suspected abnormalities/ lesion(s) as detected by previous imaging examinations (including the fetal imaging) that need to be investigated by contrast-enhanced MRI of any body regio...
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004848 10029815 Nuclear magnetic resonance imaging LLT
    22.1 100000004848 10058644 Nuclear magnetic resonance imaging whole body LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000827-11 Sponsor Protocol Number: T50/2021 Start Date*: 2022-09-02
    Sponsor Name:Turku University Hospital
    Full Title: Clinical use of USPIO contrast media in the assessment of pelvic lymph node metastasis in rectal cancer.
    Medical condition: Pelvic lymph node metastasis in rectal cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-004170-25 Sponsor Protocol Number: MH-110 Start Date*: Information not available in EudraCT
    Sponsor Name:Bracco Imaging S.p.A.
    Full Title: A PHASE III, MULTI-CENTER, OPEN-LABEL STUDY TO EVALUATE SAFETY AND EFFICACY OF MULTIHANCE® AT THE DOSE OF 0.10 mmol/kg IN MAGNETIC RESONANCE IMAGING OF THE CENTRAL NERVOUS SYSTEM IN PEDIATRIC PA...
    Medical condition: imaging diagnosis of highly suspected or known brain and/or spine disease, which are known to impair the Blood Brain Barrier Function
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004746-33 Sponsor Protocol Number: 310123 Start Date*: 2008-09-17
    Sponsor Name:Bayer HealthCare Pharmaceuticals INC
    Full Title: A multicenter, randomized, double-blind, crossover, phase 3 study to determine the safety and efficacy of gadobutrol 1.0 molar (Gadovist®) in patients referred for contrast-enhanced MRI of the cent...
    Medical condition: Male and female patients of any ethnic group who are referred for a contrast-enhanced MRI of the CNS based on current clinical symptoms or results of a previous imaging procedure.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061816 Diagnostic procedure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-006135-29 Sponsor Protocol Number: PH-107 Start Date*: 2012-09-03
    Sponsor Name:Bracco Imaging S.p.A.
    Full Title: PHASE IV, DOUBLE-BLIND, MULTI-CENTER, RANDOMIZED, CROSSOVER STUDY TO COMPARE 0.1 mmol/kg OF PROHANCE® WITH 0.1 mmol/kg OF GADOVIST®/GADAVIST™ IN MAGNETIC RESONANCE IMAGING (MRI) OF THE BRAIN (TRUTH)
    Medical condition: Have confirmed or are highly suspected of brain disease likely to enhance as determined by the following: clinical/neurological symptomatology; diagnostic testing, such as CT or previous MRI exam...
    Disease: Version SOC Term Classification Code Term Level
    15.0 10022891 - Investigations 10029820 Nuclear magnetic resonance imaging gadolinium-enhanced LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-000206-23 Sponsor Protocol Number: MH-123 Start Date*: 2009-09-15
    Sponsor Name:BRACCO IMAGING
    Full Title: PHASE IV, DOUBLE-BLIND, MULTI-CENTER, RANDOMIZED, CROSSOVER STUDY TO COMPARE 0.1 mmol/kg OF MULTIHANCE WITH 0.1 mmol/kg OF GADOVIST IN MAGNETIC RESONANCE IMAGING (MRI) OF THE BRAIN (MERIT)
    Medical condition: Subjects with confirmed or highly suspected brain tumor(s) (primary or secondary)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029818 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2006-001680-33 Sponsor Protocol Number: MH-130 Start Date*: 2006-06-23
    Sponsor Name:BRACCO IMAGING
    Full Title: Phase IV, Double-blind, Multi-center, Randomized, Cross-over Study to Compare 0.10 mmol/kg of MultiHance R with 0.10 mmol/kg of Omniscan R in Magnetic Resonance Imaging MRI of the Brain
    Medical condition: patients sent to the sites with a request for assessment/diagnoses of certain/suspected brain neoplasms
    Disease: Version SOC Term Classification Code Term Level
    6.1 10029816 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004613-18 Sponsor Protocol Number: MH-131 Start Date*: 2007-06-04
    Sponsor Name:BRACCO IMAGING
    Full Title: Phase III, Multicenter, Double-blind, Randomized, Crossover Study to Compare MultiHancE with MagnevisT in Contrast-Enhanced MagnetiC Resonance Imaging MRI of the BreasT. - DETECT -
    Medical condition: patiens with breast lesions which are highly suspicious or already known for malignancy which are requested for MRI
    Disease: Version SOC Term Classification Code Term Level
    6.1 10006279 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) DE (Completed) GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2004-004700-20 Sponsor Protocol Number: 2104-02 Start Date*: 2005-03-11
    Sponsor Name:Epix Pharmaceuticals, Inc.
    Full Title: Phase II Feasibility study of safety and efficacy of Magnetic Resonance Imaging of Thrombi with EP-2104R in the detection in Venous Thromboembolism (VTE)
    Medical condition: Detection of venous thromboembolism
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003886-33 Sponsor Protocol Number: MH-148 Start Date*: 2014-02-28
    Sponsor Name:Bracco Imaging S.p.A.
    Full Title: PHASE IV, DOUBLE-BLIND, MULTI-CENTER, RANDOMIZED, TWO-ARM CROSSOVER STUDY TO COMPARE 0.1 mmol/kg OF MULTIHANCE® WITH 0.1 mmol/kg OF DOTAREM® AND 0.05 mmol/kg OF MULTIHANCE® WITH 0.1 mmol/kg OF DOTA...
    Medical condition: Patients have confirmed or are highly suspected to have brain tumor(s) (primary or secondary), as determined by: • clinical/neurological symptomatology; • diagnostic testing, such as CT or previ...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004848 10029820 Nuclear magnetic resonance imaging gadolinium-enhanced LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2011-005909-79 Sponsor Protocol Number: PRIGA Start Date*: 2012-04-12
    Sponsor Name:Fundació Clínic per a la Recerca Biomèdica
    Full Title: Magnetic resonance with gadoxetic acid for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis. Evaluation of its impact for the non-invasive diagnosis.
    Medical condition: hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049010 Carcinoma hepatocellular LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003835-18 Sponsor Protocol Number: GE-135-004 Start Date*: 2009-04-21
    Sponsor Name:GE Healthcare Ltd
    Full Title: A phase 2, open-label test-retest study to assess the reproducibility of quantitative measurements of 18F uptake by solid tumours using PET imaging following intravenous administration of AH111585 ...
    Medical condition: Adult subjects with solid primary or metastatic tumours 2 cm or more in diameter. Malignancies may include but are not limited to non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), gl...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003263-52 Sponsor Protocol Number: BONN_Vaso07 Start Date*: Information not available in EudraCT
    Sponsor Name:University of Bonn
    Full Title: Gadofosveset Trisodium (Vasovist®) zur kontrastverstärkten MR-Angiographie der supraaortalen Arterien und zur Darstellung der Gefäßwand in der primären Kontrastmittelpassage („first pass“) und in d...
    Medical condition: Comparision between two diagnostic methods (DSA and MRA) to evaluate supraaortale arteries using three different contrast mediums
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007683 Carotid angiography LLT
    9.1 10057784 MRI angiography LLT
    9.1 10065324 Digital subtraction angiography LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004701-23 Sponsor Protocol Number: 2104-03 Start Date*: 2005-03-14
    Sponsor Name:Epix Pharmaceuticals, Inc.
    Full Title: Phase II feasibility study to evaluate the safety and efficacy of EP-2104R for Magnetic Resonance Imaging of thrombi in the arterial vasculature and cardiac chambers
    Medical condition: Detection of thrombi in the arterial vasculature and cardiac chambers
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002274-22 Sponsor Protocol Number: MH-127 Start Date*: 2006-12-18
    Sponsor Name:Bracco Imaging S.p.A.
    Full Title: A PHASE IIIB, DOUBLE-BLIND, MULTI-CENTER, RANDOMIZED, CROSS-OVER STUDY TO COMPARE 0.1 MMOL/KG OF MULTIHANCE® WITH 0.1 MMOL/KG OF MAGNEVIST® FOR CONTRAST-ENHANCED MAGNETIC RESONANCE ANGIOGRAPHY (CE-...
    Medical condition: Subjects with moderate-to-severe peripheral arterial disease based on the Fontaine’s staging of peripheral arterial occlusive disease classes IIb, III and IV
    Disease: Version SOC Term Classification Code Term Level
    8.1 10062585 Peripheral arterial occlusive disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-006259-12 Sponsor Protocol Number: 1814 Start Date*: 2012-09-03
    Sponsor Name:Jules Bordet Institute
    Full Title: Phase II study on prospective evaluating the quantification of total choline by magnetic resonance spectroscopy (MRS) in breast tumours as an early predictive marker of neoadjuvant chemotherapy res...
    Medical condition: Early breast cancer requiring neoadjuvant chimiotherapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001431-31 Sponsor Protocol Number: EMR700692-007 Start Date*: 2013-05-02
    Sponsor Name:Merck KGaA
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase II trial to investigate the efficacy and safety of 30 mcg and 100 mcg AS902330 given as one cycle of three intra-a...
    Medical condition: Knee Cartilage Injury
    Disease: Version SOC Term Classification Code Term Level
    15.1 10022117 - Injury, poisoning and procedural complications 10007710 Cartilage injury PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004418-17 Sponsor Protocol Number: I-BCT-1 Start Date*: 2014-05-07
    Sponsor Name:Oslo University Hospital
    Full Title: Improved breast cancer therapy (I-BCT-1) in the neoadjuvant and metastatic setting: A phase 2 clinical trial protocol studying biological rationale for the optimal selection of treatment regimens.
    Medical condition: breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001714-15 Sponsor Protocol Number: Met.Panc.01 Start Date*: 2013-07-23
    Sponsor Name:Med. Univ. Wien, Klinik f. Innere Med. I, Onkologie
    Full Title: Phase II trial of capecitabine (Xeloda®) + nab-paclitaxel (Abraxane®) in patients with metastatic pancreatic cancer
    Medical condition: metastatic pancreatic adenocarcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2015-005715-32 Sponsor Protocol Number: SOCODIHF Start Date*: 2017-12-07
    Sponsor Name:Karolinska Institutet Stockholm, Sweden
    Full Title: SOdium-glucose CO-transporter inhibition in patients with Type 2 Diabetes and Ischemic Heart Failure (SOCODIHF)
    Medical condition: Patients with type 2 diabetes mellitus and heart failure of ischemic origin
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 21 14:21:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA